Telitacicept following plasma exchange in the treatment of subjects with recurrent neuromyelitis optica spectrum disorders: A single‐center, single‐arm, open‐label study

INTRODUCTION: Neuromyelitis optica spectrum disorders (NMOSD), mainly mediated by B cells and AQP4 antibody, has a high rate of recurrence. Telitacicept is a novel drug specifically targeting the upstream signaling for the activation of B cell with its following production of autoimmune antibodies....

Descripción completa

Detalles Bibliográficos
Autores principales: Ding, Jie, Jiang, Xianguo, Cai, Yu, Pan, Shuting, Deng, Ye, Gao, Meichun, Lin, Yan, Zhao, Nan, Wang, Ze, Yu, Haojun, Qiu, Huiying, Jin, Yuyan, Xue, Jiahui, Guo, Quan, Ni, Liping, Zhang, Ying, Hao, Yong, Guan, Yangtai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437241/
https://www.ncbi.nlm.nih.gov/pubmed/35851754
http://dx.doi.org/10.1111/cns.13904

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9437241/
https://www.ncbi.nlm.nih.gov/pubmed/35851754
http://dx.doi.org/10.1111/cns.13904

Ejemplares similares